Enjoining a Patentee from Communicating Its Patent Rights Requires a Showing of Bad Faith

Apr 13, 2020

Reading Time : 2 min

BlephEx, LLC (“BlephEx”) is the owner of U.S. Patent 9,039,718 (the “’718 patent”). The ’718 patent is generally directed to a method for treating ocular disorders by using an electromechanical device to remove debris present at the eyelid. In 2019, Myco Industries, Inc. (“Myco”) began marketing a device called the AB Max to treat anterior blepharitis, an ocular disorder. At a trade show in 2019, BlephEx and Myco both hosted booths displaying their respective products. During the show, a representative from BlephEx allegedly approached Myco and accused Myco’s AB Max product of infringing the ’718 patent. BlephEx’s representative also allegedly stated, in the presence of potential customers, that BlephEx would be “taking action.”

Following the exchange, Myco filed an action against BlephEx seeking a declaratory judgement that it was not infringing the ’718 patent. Myco also filed a motion for a preliminary injunction to enjoin BlephEx from “making false allegations” that Myco’s product infringes the ’718 patent and “making baseless threats” against Myco’s potential customers. The district court granted Myco’s motion after determining that the totality of factors for a preliminary injunction, including (1) likelihood of success on the merits, (2) irreparable injury without the injunction, (3) substantial harm to others, and (4) public interest, weighed in favor of an injunction.

On appeal, the Federal Circuit reversed. The Federal Circuit first explained that a motion seeking to enjoin a party from communicating its patent rights must demonstrate bad faith in the notice of patent rights. Here, because the district court not only failed to make a finding of bad faith, but failed to even consider the requirement, the district court abused its discretion and reversal was warranted.

In reaching its decision, the Federal Circuit declined to infer bad faith from the allegations of infringement against potential customers, who are purportedly immune from patent infringement under the “medical practitioner immunity” provision of § 287(c). The Federal Circuit rejected this argument because the preliminary injunction was not limited to allegations against Myco’s customers. It barred BlephEx from making allegations of patent infringement in general. The Federal Circuit also clarified that the plain text of § 287(c) does not state that medical practitioners are “immune from infringement,” but rather that a patentee cannot seek a remedy for such infringement. For this reason, “Myco cannot simply hide under the umbrella of § 287(c) and argue that any alleged statements regarding medical practitioner infringement were made in bad faith.”

Finally, the Federal Circuit vacated the district court’s finding of a “strong likelihood of success” on the non-infringement claim. The district court’s determination that the AB Max likely does not infringe the ’718 patent was predicated on the finding that the AB Max is promoted for the treatment of anterior blepharitis while the claims of the ’718 patent are directed to posterior blepharitis. The Federal Circuit held that the district court’s claim construction was faulty in a number of ways. First and foremost, the plain language of the claims does not limit the claimed method to treatment of posterior blepharitis, and the district court did not find that BlephEx disavowed treating anterior blepharitis during prosecution. Moreover, the district court’s claim construction improperly focused on BlephEx’s commercial embodiment of the invention, rather than the recited limitations of the claims.

Myco Industries, Inc. v. BlephEx, LLC, 2019-2374 (Fed. Cir. Apr. 3, 2020).

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.